Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study - PubMed (original) (raw)
Clinical Trial
. 2005 Oct 20;23(30):7512-7.
doi: 10.1200/JCO.2005.01.4829.
Affiliations
- PMID: 16234518
- DOI: 10.1200/JCO.2005.01.4829
Clinical Trial
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study
Mitch Dowsett et al. J Clin Oncol. 2005.
Abstract
Purpose: Arimidex, tamoxifen alone, or in combination (ATAC) trial of anastrozole (Arimidex) versus tamoxifen or a combination of the two in 9,366 postmenopausal patients with primary breast cancer found a significant improvement in disease-free survival and time to recurrence (TTR) for anastrozole compared with tamoxifen, that was restricted to patients with hormone receptor-positive (ie, estrogen receptor-positive [ER+] and/or progesterone receptor-positive [PgR+]) disease, the target population for these therapies. We retrospectively tested the hypothesis that this benefit might differ according to PgR status.
Patients and methods: TTR was compared between the three treatment groups for subgroups defined by ER and PgR status using Cox's proportional hazards model, with and without adjustment for baseline variables.
Results: The unadjusted hazard ratio (HR) for anastrozole versus tamoxifen for TTR was 0.74 (95% CI, 0.64 to 0.87) for women with either ER+ or PgR+ tumors. In the ER+/PgR+ subgroup (n = 3,834) the HR was 0.84 (95% CI, 0.69 to 1.02) compared with 0.43 (95% CI, 0.31 to 0.61) in the ER+/PgR-negative (PgR-) subgroup (n = 880). In the adjusted model the HRs were 0.83 and 0.45, respectively.
Conclusion: Time to recurrence was longer for anastrozole- than tamoxifen-treated patients in both ER+/PgR+ and ER+/PgR- subgroups, but the benefit was substantially greater in the PgR- subgroup. As this was an "exploratory" analysis, this effect should be considered as hypothesis generating and assessed prospectively in other trials comparing the adjuvant use of an aromatase inhibitor with tamoxifen.
Comment in
- Progesterone receptor and human epidermal growth factor receptor 2 status: an independent influence on the efficacy of endocrine therapy in breast cancer?
Ponzone R, Maggiorotto F, Robba C, Fuso L, Sismondi P. Ponzone R, et al. J Clin Oncol. 2006 Mar 20;24(9):1481-2; author reply 1482. doi: 10.1200/JCO.2005.05.0286. J Clin Oncol. 2006. PMID: 16549847 No abstract available.
Similar articles
- Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A. Dowsett M, et al. J Clin Oncol. 2008 Mar 1;26(7):1059-65. doi: 10.1200/JCO.2007.12.9437. Epub 2008 Jan 28. J Clin Oncol. 2008. PMID: 18227529 Clinical Trial. - Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL; National Cancer Institute of Canada Clinical Trials Group MA.17. Goss PE, et al. J Clin Oncol. 2007 May 20;25(15):2006-11. doi: 10.1200/JCO.2006.09.4482. Epub 2007 Apr 23. J Clin Oncol. 2007. PMID: 17452676 Clinical Trial. - Focus on anastrozole and breast cancer.
Mokbel K. Mokbel K. Curr Med Res Opin. 2003;19(8):683-8. doi: 10.1185/030079903125002397. Curr Med Res Opin. 2003. PMID: 14687437 Review. - Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
Dodwell D, Williamson D. Dodwell D, et al. Cancer Treat Rev. 2008 Apr;34(2):137-44. doi: 10.1016/j.ctrv.2007.09.004. Epub 2007 Nov 14. Cancer Treat Rev. 2008. PMID: 18006236 Review.
Cited by
- Aromatase inhibitors: the journey from the state of the art to clinical open questions.
Generali D, Berardi R, Caruso M, Cazzaniga M, Garrone O, Minchella I, Paris I, Pinto C, De Placido S. Generali D, et al. Front Oncol. 2023 Dec 22;13:1249160. doi: 10.3389/fonc.2023.1249160. eCollection 2023. Front Oncol. 2023. PMID: 38188305 Free PMC article. Review. - Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers.
Chen HL, Huang FB, Chen Q, Deng YC. Chen HL, et al. BMC Cancer. 2023 Sep 8;23(1):841. doi: 10.1186/s12885-023-11368-2. BMC Cancer. 2023. PMID: 37684569 Free PMC article. - Development and validation of a predictive nomogram for the specific mortality risk of luminal B breast cancer patients: a competing risk model based on real populations.
Zhao H, Yan H, Chen L, Li Y. Zhao H, et al. Transl Cancer Res. 2023 Apr 28;12(4):965-979. doi: 10.21037/tcr-23-484. Transl Cancer Res. 2023. PMID: 37180675 Free PMC article. - Survival is associated with repressive histone trimethylation markers in both HR-positive HER2-negative and triple-negative breast cancer patients.
Wang B, Zhou M, Shi YY, Chen XL, Ren YX, Yang YZ, Tang LY, Ren ZF. Wang B, et al. Virchows Arch. 2023 Jun;482(6):1047-1056. doi: 10.1007/s00428-023-03534-5. Epub 2023 Apr 15. Virchows Arch. 2023. PMID: 37059917 - The Role of Progesterone Receptors in Breast Cancer.
Li Z, Wei H, Li S, Wu P, Mao X. Li Z, et al. Drug Des Devel Ther. 2022 Jan 26;16:305-314. doi: 10.2147/DDDT.S336643. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35115765 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous